Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Despite winning US Food and Drug Administration approval for a new antibiotic last year, Achaogen has filed for bankruptcy. The South San Francisco–based biotech firm launched the antibiotic, Zemdri (plazomicin), in July for adults with complicated urinary tract infections. However, by the end of the year the drug had brought in only $800,000 in sales. Achaogen hopes to sell off its assets, including Zemdri, by June 13.
This article has been sent to the following recipient: